Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WinHealth Acquires Two Rare Disease Therapies from Quoin Pharma

publication date: Jun 15, 2022

Hong Kong WinHealth Pharma, a rare disease company, acquired Greater China rights for two topical rare skin disease medications from Quoin Pharma (NSDQ: QNRX) of Virginia. WinHealth will have rights to Quoin’s lead candidate, QRX003, for Netherton Syndrome and QRX004 for Epidermolysis Bullosa. Netherton Syndrome is a skin shedding disorder caused by the lack of the LEKTI protein. Epidermolysis bullosa is a group of rare inherited skin fragility disorders caused by mutations in at least 20 different genes causing blisters and wounds. Specific details of the transaction were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital